Innovative approaches in breast cancer therapy: repurposing nanocarriers for enhanced outcomes

Breast cancer is one of the most prevalent cancers globally, affecting over 685,000 women annually. While traditional treatment modalities such as surgery, chemotherapy, and radiation therapy have contributing to improved survival rates; however, they are often plagued by limitations such as systemic toxicity, lack of targeted therapy, development of resistance, and collateral damage to healthy tissues. While targeted therapies and endocrine treatment have provided more personalized approaches, challenges like side effects and limited effectiveness in specific subtypes remain. Nanotechnology offers new avenues for addressing these challenges, particularly through the development of advanced nanocarrier systems. Nanocarrier systems are designed to enhance drug targeting, improve bioavailability, reduce side effects, and combat drug resistance. These advanced delivery systems facilitate controlled release, higher drug concentration at target sites, and the potential for combination therapies, thus improving treatment outcomes. Breast cancer clinical trials assess treatment effectiveness, providing critical insights through their statuses and outcomes. The aim of this study is to explore the potential of nanocarrier systems in overcoming the limitation of traditional therapy, enhancing the effectiveness of drug delivery, and enhancing overall treatment outcomes for breast cancer treatment.